● Third-quarter results were scheduled for the open on November 10.
● FreeCash Flowwas $19.11 billion in the quarter.
Xilio Therapeutics, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 10, 2026, covering the fiscal quarter ended September 30, 2026.
Director Richard H. Fearon filed a Form 4 with the SEC on November 10, 2026, disclosing a purchase of 6,000 ordinary shares of CRH Public Ltd Co on November 6, 2026.
Key HighlightsMicrovast Holdings (NASDAQ:MVST) was indicated at USD 0.3139 pre-market on Tuesday, November 10, 2026, down 49.17% from a calculated prior close of USD 0.6175 after the third-quarter report.Third-quarterRevenuefell 62.8% to USD 45.8 million from USD 123.3 million, and the net loss widened to …
The outlook added to the disappointment. Fourth-quarter revenue guidance of USD 133 million to USD 136 million points to flat to 2% growth, below expectations, with adjusted EBITDA of USD 18 million to USD 23 million and positive free cash flow. For the full …
Key HighlightsFutureFuel (NYSE:FF) was indicated at USD 3.60 pre-market on Tuesday, November 10, 2026, down 28.99% from a calculated prior close of USD 5.07 after results released on November 9.Third-quarterRevenuerose 361.3% to USD 104.7 million from USD 22.7 million, but the net loss was …
Key HighlightsIonis Pharmaceuticals (NASDAQ:IONS) fell about 28% on November 9, 2026, closing near USD 28.15 in its worst single-day decline since May 2016, onVolumeof about 6.5 million shares.The company cut its 2026 Tryngolza sales forecast to about USD 50 million from USD 100 million …
Key HighlightsiHeartMedia (NASDAQ:IHRT) was indicated at USD 1.28 pre-market on Tuesday, November 10, 2026, down 27.68% from a calculated prior close of USD 1.77 after results released on November 9.Third-quarterRevenuerose 3.3% to USD 1,029.8 million, but adjusted EBITDA fell 16.7% to USD 170.5 million …
Remlifanserin is the company's main bet on a much larger market. Alzheimer's disease psychosis, which involves hallucinations and delusions, affects a large and growing population with few approved treatments. In the Phase 2 portion of the RADIANT study, reported in September 2026, 326 patients …